Shukui Qin
A5043672686- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Cancer Mechanisms and Therapy
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Research Studies
- Renal cell carcinoma treatment
- Cancer, Lipids, and Metabolism
- Liver Disease Diagnosis and Treatment
- Liver physiology and pathology
- Esophageal Cancer Research and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Hepatitis B Virus Studies
- Fibroblast Growth Factor Research
- Ferroptosis and cancer prognosis
- HER2/EGFR in Cancer Research
- Neuroendocrine Tumor Research Advances
- Cancer-related molecular mechanisms research
Heilongjiang University of Chinese Medicine
2025
81th Hospital of PLA
2015-2024
Jiangsu Cancer Hospital
2014-2024
Nanjing University of Chinese Medicine
2018-2024
Nanjing General Hospital of Nanjing Military Command
2019-2024
China Pharmaceutical University
2023-2024
Sichuan University
2010-2024
Affiliated Hospital of Southwest Medical University
2024
Nanjing Medical University
2013-2023
Chinese People's Liberation Army
2010-2023
The combination of atezolizumab and bevacizumab showed encouraging antitumor activity safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.
IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free (PFS) compared with sorafenib in patients unresectable hepatocellular carcinoma at the primary analysis (after a median 8.6 months of follow-up). We present updated data after 12 additional follow-up.Patients systemic treatment-naive, were randomized 2:1 receive 1,200 mg 15 mg/kg intravenously every 3 weeks or 400 orally twice daily this open-label, phase III...
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients advanced/metastatic squamous cell carcinoma or adenocarcinoma of the esophagus, that progressed one prior therapy, to pembrolizumab 200 mg every 3 weeks for up 2 years chemotherapy (investigator’s choice paclitaxel, docetaxel, irinotecan). Primary end points were...
BackgroundA single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed encouraging clinical activity and safety in a phase 2 trial unresectable hepatocellular carcinoma.MethodsIn this global, open-label, 3 trial, the majority patients we enrolled with carcinoma no previous systemic treatment were randomly assigned...
Purpose There is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing progression after two or more lines of chemotherapy. We assessed the efficacy and safety apatinib, a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, in gastroesophageal junction adenocarcinoma whom at least prior chemotherapy had failed. Patients Methods This was randomized, double-blind, placebo-controlled phase III trial. from 32 centers...
Purpose Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. Patients and Methods were stratified randomly assigned receive 37.5 mg once per day 400 twice day. Primary end point overall survival (OS). Results Early termination occurred for futility safety reasons. A total of 1,074 patients the study (sunitinib arm, n = 530; 544). For sorafenib, respectively, median OS 7.9 versus 10.2 months (hazard ratio [HR], 1.30;...
Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast receptors that are implicated in the pathogenesis hepatocellular carcinoma (HCC). Our multinational, randomized, double-blind, phase III trial compared brivanib with sorafenib as first-line treatment for HCC.Advanced HCC patients who had no prior systemic therapy were randomly assigned (ratio, 1:1) to receive 400 mg twice daily orally (n = 578) or 800 once 577). Primary end point was overall survival (OS)....
This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.Patients were randomly assigned a 1:1 ratio to 17.5 mg once daily or 400 twice daily. Patients stratified by region (Outside Asia, Japan, rest Asia), Eastern Cooperative Oncology Group performance score (ECOG PS; 0 1), vascular invasion extrahepatic spread (yes no), hepatitis B virus (HBV) infection no). The...
To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma.Patients HER2-positive adenocarcinoma were randomly assigned at a one-to-one ratio CapeOx plus 1,250 mg or placebo daily. Primary end point was overall survival (OS) centrally confirmed HER2 amplification primary population.A total 545 assigned, 487 comprised population....
To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced hepatocellular carcinoma (HCC) a multicenter, multinational, randomized, phase III trial.
Patients with metastatic gastric cancer (mGC) who do not respond to or experience progression second-line chemotherapy have no treatment options that clearly confer a survival benefit. This trial investigated the safety and efficacy of apatinib, an inhibitor vascular endothelial growth factor receptor, as option for heavily pretreated patients mGC.Patients experienced failure at least two chemotherapeutic regimens were randomly assigned receive placebo (group A), apatinib 850 mg once daily...
To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit efficacy versus doxorubicin.This multicenter, open-label, randomized, phase III study in mainland China, Taiwan, Korea, Thailand involved 371 age 18 75 years who had locally or metastatic HCC were ineligible for curative resection local treatment. They randomly assigned at ratio of one...
This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 as monotherapies in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring single, priming dose of (ClinicalTrials.gov identifier: NCT02519348).Patients HCC who had progressed on, were intolerant to, or refused sorafenib randomly assigned to receive T300 + D (tremelimumab 300 mg...
<h3>Importance</h3> Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options. <h3>Objective</h3> To evaluate the efficacy safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients CRC. <h3>Design, Setting, Participants</h3> FRESCO (Fruquintinib Efficacy Safety 3+ Line Colorectal Cancer Patients) was randomized, double-blind, placebo-controlled, multicenter (28...
Donafenib, a novel multikinase inhibitor and deuterated sorafenib derivative, has shown efficacy in phase Ia Ib hepatocellular carcinoma (HCC) studies. This study compared the safety of donafenib versus as first-line therapy for advanced HCC.This open-label, randomized, parallel-controlled, multicenter II-III trial enrolled patients with unresectable or metastatic HCC, Child-Pugh score ≤ 7, no prior systemic from 37 sites across China. Patients were randomly assigned (1:1) to receive oral...